Non-steroidal anti-inflammatory drugs and risk of venous thromboembolism: A systematic review and meta-analysis

Rheumatology (United Kingdom)

Volumn 54, Issue 4, 2014, Pages 736-742

  Ungprasert, Patompong ^a   Srivali, Narat ^a   Wijarnpreecha, Karn ^b,c   Charoenpong, Prangthip ^d   Knight, Eric L ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b CHIANG MAI UNIVERSITY   (Thailand)

^c Faculty of Medicine Chiang Mai University   (Thailand)

^d ADVOCATE ILLINOIS MASONIC MEDICAL CENTER   (United States)

Author keywords

Epidemiology; Meta analysis; Nsaids; Respiratory; Systematic review

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; FOLLOW UP; HAZARD RATIO; HUMAN; LUNG EMBOLISM; META ANALYSIS (TOPIC); PREVALENCE; PRIORITY JOURNAL; QUALITY CONTROL; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; STANDARDIZED INCIDENCE RATIO; VENOUS THROMBOEMBOLISM;

EID: 84926453669     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu408     Document Type: Article

References (25)

1. Naess IA, Christiansen SC, Romundstad P et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007;5:692-9.
2. Cushman M, Tsai AW, White RH et al. Deep venous thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004;117:19-25.
3. Stein PD, Kayali F, Olson RE. Estimated case fatality rate of pulmonary embolism, 1979-1998. Am J Card 2004;93:1197-9.
4. Ungprasert P, Kittanamongkolchai W, Price CD et al. What is the ''safest'' non-steroidal anti-inflammatory drugs? Am Med J 2012;3:115-23.
5. Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
6. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective of cyclooxygenase 2. JAMA 2006;296:1633-44.
7. Franchini M, Mannucci PM. Venous and arterial thrombosis:different sides of the same coin? Eur J Intern Med 2008;19:476-81.
8. Prandoni P. Link between arterial and venous disease. J Intern Med 2007;262:341-50.
9. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603-5.
10. Tsai AW, Cushman M, Rosamond WD et al. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002;162:1182-9.
11. Huerta C, Johansson S, Wallander MA, Garcia-Rodriguez LA. Risk factors and short-term mortality of venous thromboembolism diagnosed in primary care setting in the United Kingdom. Arch Intern Med 2007;167:935-43.
12. Lacut K, van der Maaten J, Le Gal G et al. Antiplatelet drugs and risk of venous thromboembolism: result from the EDITH case-control study. Haematologica 2008;93:1117-8.
13. Biere-Rafi S, Di Nisio M, Gerdes V et al. Non-steroidal antiinflammatory drugs and risk of pulmonary embolism. Pharmacoepidemiol Drug Saf 2011;20:635-42.
14. Schmidt M, Christiansen CF, Horvath-Puho E et al. Nonsteroidal anti-inflammatory drug use and risk of venous thromboembolism. J Thromb Haemost 2011;9:1326-33.
15. Bergendal A, Adami J, Bahmanyar S et al. Non-steroidal anti-inflammatory drug use and venous thromboembolism in women. Pharmacoepidemiol Drug Saf 2013;22:658-66.
16. Davies HT, Crombie IK, Tavakoli M. When can odds ratio mislead? BMJ 1998;316:989-91.
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trial 1986;7:177-88.
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
19. Graff J, Skarke C, Klinkhardt U et al. Effect of selective COX-2 inhibition on prostanoids and platelet physiology in young healthy volunteers. J Thromb Haemost 2007;12:2376-85.
20. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296:1633-44.
21. Anderson DR, Dunbar MJ, Bohm ER et al. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med 2013;158:800-6.
22. Larocca A, Cavallo F, Bringhen S et al. Aspirin or enoxaprarin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 2012;119:933-9.
23. Ungprasert P, Srivali N, Spanuchart I, Thongprayoon C, Knight EL. Risk of venous thromboembolism in patients with rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol 2014;33:297-304.
24. Johannesdottir SA, Schmidt M, Horvath-Puho., Sorensen HT. Autoimmune skin and connective tissue diseases and risk of venous thromboembolism: a population- based case-control study. J Thromb Haemost 2012;10:815-21.
25. Ungprasert P, Sanguankeo A. Risk of venous thromboembolism in patients with idiopathic inflammatory myositis: a systematic review and meta-analysis. Rheumatol Int 2014. [Epub ahead of print].